Encompass Wealth Advisors Trims Amgen Stake by Over 50%

The investment firm reduced its holdings in the biotech giant during the fourth quarter.

Apr. 10, 2026 at 8:05am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up of heavy, industrial banking and financial machinery, conveying the complex, powerful systems that underpin the biotech sector.An extreme close-up of the inner workings of the biotech industry, where institutional investors like Encompass Wealth Advisors carefully manage their portfolios.Thousand Oaks Today

Encompass Wealth Advisors LLC lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 50.1% during the 4th quarter, according to the company's recent SEC filing. The firm sold 3,010 shares, leaving it with 2,997 shares of the medical research company's stock valued at $981,000.

Why it matters

This transaction reflects Encompass Wealth Advisors' shifting investment strategy and portfolio adjustments in the biotech sector. Amgen is a major player in the pharmaceutical industry, so changes to its institutional ownership can signal broader trends in the market.

The details

Encompass Wealth Advisors reduced its Amgen position by over 50% in the fourth quarter, selling 3,010 shares. The firm now holds 2,997 shares of the biotech company, valued at $981,000 as of the latest filing. This move comes as Amgen continues to navigate a competitive landscape, with the company reporting mixed financial results in recent quarters.

  • The transaction occurred during the fourth quarter of 2025.
  • Encompass Wealth Advisors filed the details of the trade with the SEC on April 10, 2026.

The players

Encompass Wealth Advisors LLC

An investment management firm that oversees a portfolio of stocks, bonds, and other assets for its clients.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Amgen's upcoming earnings reports and any further changes to the company's institutional ownership as the biotech landscape continues to evolve.

The takeaway

This transaction highlights the dynamic nature of portfolio management, as investment firms like Encompass Wealth Advisors make strategic adjustments to their holdings based on their assessment of market conditions and the performance of individual companies.